Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Phase 2 Recruiting
68 enrolled
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Phase 1 Recruiting
18 enrolled
TROPHY-15
Phase 3 Recruiting
594 enrolled
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Phase 1 Recruiting
30 enrolled
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
42 enrolled
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Phase 1 Recruiting
125 enrolled
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Phase 1/2 Recruiting
20 enrolled
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Phase 2 Recruiting
508 enrolled
Gilteritinib for the Treatment of ALK NSCLC
Phase 1 Recruiting
30 enrolled
MRD-positive AML Clinical Study
Phase NA Recruiting
120 enrolled
SEQUENCE
Phase 2 Recruiting
60 enrolled
OGILAR
Phase 2 Recruiting
33 enrolled
GMCAII
Phase 2 Recruiting
500 enrolled